{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:57:45Z","timestamp":1790229465427,"version":"4.1.0"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>This article provides an update on the most recent advances in diagnostic procedures and therapeutic approaches for myasthenia gravis, spanning from autoantibody and neuroelectrophysiological tests as diagnostic tools, to innovative and promising treatments based on biological drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>Novel studies performed by cell-based assays (CBAs) indicate an improvement in the chance of identifying serum autoantibodies in myasthenic patients. Clinical trials on the use of biological drugs were recently concluded, providing important data on safety and efficacy of eculizumab, efgartigimod and amifampridine phosphate: the first, a complement blocker, showed long-term safety and efficacy in acetylcholine receptor (AChR)-positive myasthenic patients with refractory generalized disease; the second, the neonatal Fc receptor blocker, was well tolerated and clinically effective in both AChR-specific and muscle-specific kinase receptor (MuSK)-positive patients; the third, a blocker of presynaptic potassium channels, was found to be well tolerated and effective in MuSK-positive patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>CBAs can lead to a significant reduction of seronegative patients, improving myasthenia gravis diagnostic process. New biological drugs offer innovative approaches to treat myasthenic patients with generalized disease, promising to change the paradigm of treatment and to significantly enhance therapeutic success within a precision medicine framework.<\/jats:p><\/jats:sec>","DOI":"10.1097\/bor.0000000000000647","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T16:41:03Z","timestamp":1565023263000},"page":"623-633","source":"Crossref","is-referenced-by-count":63,"title":["Diagnosis and treatment of myasthenia gravis"],"prefix":"10.1097","volume":"31","author":[{"given":"Renato","family":"Mantegazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cavalcante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/nyas.13519","article-title":"Thymus involvement in early-onset myasthenia gravis","volume":"1412","author":"Cron","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","article-title":"Italian recommendations for the diagnosis and treatment of myasthenia gravis","volume":"40","author":"Evoli","year":"2019","journal-title":"Neurol Sci"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/nyas.13537","article-title":"Developing treatment guidelines for myasthenia gravis","volume":"1412","author":"Sanders","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"1756285617749134","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol Clin"},{"key":"R8-20230828","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2019.04.017","article-title":"Incidence Epidemiology, and transformation of ocular myasthenia gravis: a population based study","author":"Hendricks","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","article-title":"MuSK autoantibodies in myasthenia gravis detected by cell based assay-A multinational study","volume":"284","author":"Tsonis","year":"2015","journal-title":"J Neuroimmunol"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/WCO.0000000000000596","article-title":"Myasthenia gravis: from autoantibodies to therapy","volume":"31","author":"Mantegazza","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/mus.26404","article-title":"Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis","volume":"59","author":"Clifford","year":"2019","journal-title":"Muscle Nerve"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.autrev.2018.07.011","article-title":"Characterization of the thymus in Lrp4 myasthenia gravis: four cases","volume":"18","author":"Koneczny","year":"2019","journal-title":"Autoimmun Rev"},{"key":"R16-20230828","doi-asserted-by":"crossref","DOI":"10.1111\/ene.13979","article-title":"Clinical analysis of Chinese anti-LRP4 antibodies in patients with myasthenia gravis","author":"Li","year":"2019","journal-title":"Eur J Neurol"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jneuroim.2008.07.012","article-title":"Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 on a 20-year experience","volume":"201-202","author":"Maggi","year":"2008","journal-title":"J Neuroimmunol"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00415-019-09225-z","article-title":"Thymomatous myasthenia gravis: novel association with HLA DQB1\u221705:01 and strengthened evidence of high clinical and serological severity","volume":"266","author":"Massa","year":"2019","journal-title":"J Neurol"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/acn3.26","article-title":"LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients","volume":"1","author":"Tzartos","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cca.2015.07.030","article-title":"An update on laboratory diagnosis in myasthenia gravis","volume":"449","author":"Oger","year":"2015","journal-title":"Clin Chim Acta"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10072-017-3026-2","article-title":"Diagnostics of myasthenic syndromes: detection of anti-AChR and anti-MuSK antibodies","volume":"38","author":"Andreetta","year":"2017","journal-title":"Neurol Sci"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jim.2018.06.016","article-title":"Immunostick ELISA for rapid and easy diagnosis of myasthenia gravis","volume":"460","author":"Trakas","year":"2018","journal-title":"J Immunol Methods"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1038\/s41598-019-41730-z","article-title":"Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and\/or myocarditis","volume":"9","author":"Kufukihara","year":"2019","journal-title":"Sci Rep"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/ene.13922","article-title":"Acquired neuromyotonia in thymoma-associated myasthenia gravis: a clinical and serological study","volume":"26","author":"Gastaldi","year":"2019","journal-title":"Eur J Neurol"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1016\/j.clinph.2016.09.012","article-title":"Repetitive nerve stimulation often fails to detect abnormal decrement in acute severe generalized myasthenia gravis","volume":"127","author":"Liik","year":"2016","journal-title":"Clin Neurophysiol"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/mus.26390","article-title":"Repetitive nerve stimulation test in myasthenic crisis","volume":"59","author":"Oh","year":"2019","journal-title":"Muscle Nerve"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.clinph.2019.03.033","article-title":"Repetitive ocular vestibular evoked myogenic potential stimulation for the diagnosis of myasthenia gravis: optimization of stimulation parameters","volume":"130","author":"Wirth","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis","volume":"16","author":"Benatar","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1002\/mus.10141","article-title":"The clinical impact of single-fiber electromyography","volume":"11","author":"Sanders","year":"2002","journal-title":"Muscle Nerve Suppl"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/mus.26319","article-title":"Serial stimulated jitter analysis in juvenile myasthenia gravis","volume":"58","author":"Bhatia","year":"2018","journal-title":"Muscle Nerve"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/NDT.S8915","article-title":"Current and emerging therapies for the treatment of myasthenia gravis","volume":"7","author":"Mantegazza","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2019.05.003","article-title":"Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis","volume":"402","author":"Ozawa","year":"2019","journal-title":"J Neurol Sci"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jca.21694","article-title":"Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status","volume":"34","author":"Usmani","year":"2019","journal-title":"J Clin Apher"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/mus.26032","article-title":"Infections and the relationship to treatment in neuromuscular autoimmunity","volume":"57","author":"Prior","year":"2018","journal-title":"Muscle Nerve"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/s00415-019-09222-2","article-title":"Effect of thymectomy in elderly patients with nonthymomatous generalized myasthenia gravis","volume":"266","author":"Kim","year":"2019","journal-title":"Neurology"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"R41-20230828","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","article-title":"Eculizumab improves fatigue in refractory generalized myasthenia gravis","volume":"28","author":"Andersen","year":"2019","journal-title":"Qual Life Res"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"2050312118819013","DOI":"10.1177\/2050312118819013","article-title":"Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study","volume":"6","author":"Bonanno","year":"2018","journal-title":"SAGE Open Med"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3233\/JND-180300","article-title":"Efficacy of rituximab in refractory generalized anti-AChR myasthenia gravis","volume":"5","author":"Landon-Cardinal","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jneuroim.2019.05.004","article-title":"Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis","volume":"332","author":"Jing","year":"2019","journal-title":"J Neuroimmunol"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.expneurol.2019.03.001","article-title":"Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis","volume":"317","author":"Huijbers","year":"2019","journal-title":"Exp Neurol"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/0091270011435989","article-title":"A new thiopurine S-methyltransferase haplotype associated with intolerance to azathioprine","volume":"53","author":"Colleoni","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/FPC.0000000000000257","article-title":"A novel ABCC6 haplotype is associated with azathioprine drug response in myasthenia gravis","volume":"27","author":"Colleoni","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"R52-20230828","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fneur.2017.00230","article-title":"The role of osteopontin and its gene on glucocorticoid response in myasthenia gravis","volume":"8","author":"Xie","year":"2017","journal-title":"Front Neurol"},{"key":"R53-20230828","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1136\/ard.2009.126441","article-title":"Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity","volume":"69","author":"Kormelink","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R54-20230828","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10067-010-1674-1","article-title":"Normalization of serum-free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity","volume":"30","author":"Chiche","year":"2011","journal-title":"Clin Rheumatol"},{"key":"R55-20230828","first-page":"9646209","article-title":"Serological immunoglobulin-free light chain profile in myasthenia gravis patients","author":"Basile","year":"2018","journal-title":"J Immunol Res"},{"key":"R56-20230828","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fimmu.2019.00015","article-title":"Cytokine targeting by miRNAs in autoimmune diseases","volume":"10","author":"Salvi","year":"2019","journal-title":"Front Immunol"},{"key":"R57-20230828","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/bib\/bbs082","article-title":"Pharmaco-miR: linking microRNAs and drug effects","volume":"15","author":"Rukov","year":"2014","journal-title":"Brief Bioinform"},{"key":"R58-20230828","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.13510","article-title":"Circulating microRNAs as potential biomarkers in myasthenia gravis patients","volume":"1412","author":"Punga","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R59-20230828","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.autrev.2018.01.008","article-title":"Analysis of microRNA expression in the thymus of Myasthenia Gravis patients opens new research avenues","volume":"17","author":"Cron","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R60-20230828","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3389\/fimmu.2019.00539","article-title":"Causes and consequences of miR-150-5p dysregulation in myasthenia gravis","volume":"10","author":"Cron","year":"2019","journal-title":"Front Immunol"},{"key":"R61-20230828","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jneuroim.2018.05.003","article-title":"Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis","volume":"321","author":"Sabre","year":"2018","journal-title":"J Neuroimmunol"},{"key":"R62-20230828","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/acn3.692","article-title":"miR-30e-5p as predictor of generalization in ocular myasthenia gravis","volume":"6","author":"Sabre","year":"2019","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T21:13:41Z","timestamp":1695071621000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000647","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}